Stealth Pushes for Faster US FDA Review Of Barth Syndrome Drug As Funds Dwindle

 
• By Sue Sutter
  
Hourglass with coins
Stealth says it may run out of money while it waits for the six-month review clock to run. (Shutterstock)

More from Complete Response Letters

More from United States